Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Wallace, M. R.
space
  arrow  Oldfield, E. C.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REPLY

Does Acyclovir Worsen Late Varicella?

right arrow Mark R. Wallace; Stephanie K. Brodine; and Edward C. Oldfield

1 March 1993 | Volume 118 Issue 5 | Pages 394-395


IN RESPONSE:

We appreciate Dr. Klein's comments on our recent article. We also were puzzled by the statistically significant differences in new lesion formation and maximum number of lesions favoring placebo in the late treatment group (24 to 72 hours after rash onset). We suspect that these differences are partially the result of the randomization of a relatively small group of patients (72) yielding a late placebo group with a lesion count at entry of 20% less than that of the acyclovir group. Not surprisingly, given their initially lower lesion counts, the placebo group had a lower maximum number of lesions. Despite the favoring of the placebo group by other parameters, the duration of fever was slightly less in the acyclovir-treated group. We can think of no reason why acyclovir would worsen the course of varicella in late-presenting patients. We agree with Dr. Klein's conclusion that delayed administration (> 24 hours after rash onset) of acyclovir in patients with uncomplicated varicella is unwarranted.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.





box Article
 arrow  Table of Contents                
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Wallace, M. R.
space
  arrow  Oldfield, E. C.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online